Previous studies have shown a higher prevalence of cardiometabolic diseases among patients with psoriasis compared to non-psoriatics. However, little attention has been paid to the effects of systemic antipsoriatic drugs. The aim of this study was to investigate the association between psoriasis and these comorbidities, comparing untreated patients with psoriasis and population-based control non-psoriatic patients. A hospital-based case-control study included 122 patients with plaque-type psoriasis and 122 age-and gender-matched controls. Patients who ever received systemic antipsoriatic drugs were excluded. There were no signifi cant differences between psoriatic patients and controls regarding the prevalence of hypertension (p=0.311), coronary heart disease (p=0.480), diabetes (p=0.641), myocardial infarction (p=0.71), stroke (2.4% vs. 2.4%, p=1.00) and metabolic syndrome (p=0.764). The prevalence of hypertriglyceridemia in patients with psoriasis and controls was 41.8% and 28.7%, respectively (OR 1.78, 95% CI 1.04-3.04, p=0.032). Furthermore, signifi cant differences were observed in mean triglyceride levels (p=0.013). Smoking was signifi cantly more often reported in psoriatic patients compared to controls. Patients with psoriasis also had a higher mean BMI (26.24, SD 4.42) compared with controls (24.73, SD 3.86), p=0.005. Psoriasis showed a statistically signifi cant association with BMI obesity classifi cation [2(4)=11.560, p=0.02]. The prevalence of cardiovascular and metabolic comorbidities was not signifi cantly higher in patients with plaquetype psoriasis who were never treated with systemic antipsoriatic drugs, compared to population-based non-psoriatic controls. Our data suggest that systemic antipsoriatic drugs may play an important role in the development of these comorbidities. However, this study confi rms that untreated psoriasis patients have three major modifi able increased cardiovascular risk factors, such as smoking, obesity and hypertriglyceridemia.
P soriasis is a chronic, relapsing, infl ammatory skin disease with an estimated prevalence worldwide ranging from 0.91% (USA) to 8.5% (Norway) (1) . Th e most common type of psoriasis is plaque psoriasis, accounting for around 80% of cases. Approximately 20% of aff ected individuals have moderate-to-severe psoriasis (2) . Th e traditional belief about psoriasis is that it is a skin disease without visceral involvement. However, by the end of the 20th century, the psoriasis model had evolved to become a disorder of the skin and joints. Nevertheless, this concept has been challenged in recent years. Currently, psoriasis is considered to be a Th 1/Th 17-mediated infl ammatory disease, characterized by chronically elevated levels of proinfl ammatory cytokines (3) . Recently it has been classifi ed as an immunemediated infl ammatory disease (IMID) with high risk of systemic comorbidities (4) .
Comorbidity in psoriasis has become one of the most engrossing topics in dermatology in the past fi ve years. A mere search of the terms "psoriasis and comorbidities" in Pubmed shows more than 300 articles published over the last decade.
In 2011, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) identifi ed comorbidities as one of three priority research areas in psoriasis and psoriatic arthritis (5) . Traditionally, comorbidity has been defi ned as the presence of two or more diseases or conditions in the same individual at the same time (6). Klein et al. argue that comorbidity may occur for a variety of reasons. Th ere is a possibility that comorbitity occurs due to the following: conjuction of independent risk factors; shared or overlapping risk factors; one disorder causes another; variable expression of one disorder; independent coincidence (7) .
Th ere is a growing evidence that psoriasis is associated with a number of systemic comorbidities, including psoriatic arthritis (PsA), obesity, hypertension, diabetes mellitus, hyperlipidemia, metabolic syndrome, cardiovascular disease (CVD), Crohn's disease, lymphoma, malignancies and multiple sclerosis, as well as mental health comorbidity including anxiety, depression, smoking, alcoholism, and eating disorder (8) (9) (10) (11) (12) (13) (14) (15) . However, the exact mechanisms standing behind these associations are still uncertain. Th e relationship between psoriasis and CVD is probably associated with the underlying chronic infl ammation that exists in psoriasis, as a consequence of increased levels of proinfl ammatory cytokines (16) . Th e elevated tumor necrosis factor-alpha (TNF-) levels have been found in the skin lesions and sera of patients with psoriasis and increased serum levels have been shown to correlate with disease activity (17) . Th e relationship between psoriasis and associated diseases is complex, making it diffi cult to identify direct relationships ( Figure 1 ). Life style factors, impaired health-related quality of life, depression, and therapeutic interventions, may be confounding. Also, several biases, such as detection bias, may aff ect observational study results (18) .
Th ere is little information available on the eff ects of drugs on comorbidities. Drugs used in the treatment of psoriasis, such as acitretin, cyclosporine, and methotrexate, may adversely aff ect independent approved by the Ethics Committee of the Medical Faculty. All participants signed an informed consent.
Methods

Severity of psoriasis
Th e severity of psoriasis was assessed using the Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA). A PASI score ≤10 defi nes psoriasis as mild, whereas scores above 10 classify it as moderate or severe. Patients were classifi ed in regard to the age of onset of psoriasis; type 1: onset before the age of 40 years, and type 2: onset after the age of 40 years (22) . Th e diagnosis of psoriatic arthritis (PsA) was made using Moll and Wright criteria (23) .
Comorbidity data
A list of clinically-relevant comorbidities was derived from diagnoses included in the Charlson Comorbidity Index (21) . Chronic conditions were classifi ed using diagnoses at discharge or drug prescriptions, for example: diabetes -if use of antidiabetic drugs was registered; hypertension -if BP ≥140/90 mmHg was found, and/or current use of an antihypertensive.
Metabolic syndrome
Metabolic syndrome was diagnosed by the presence of three or more of the following criteria of the National Cholesterol Education Programme's Adult Treatment Panel III (ATP III): waist circumference > 102 cm in men and > 88 cm in women; hypertriglyceridemia > 1.7 mmol/l (150 mg/dl) or ongoing drug treatment for elevated triglycerides; high density lipoprotein (HDL) cholesterol < 1.0 mmol/l (40 mg/dl) in men and < 1.3 mmol/dl (50 mg/dl) in women or ongoing antilipidemic treatment; blood pressure > 130/85 mmHg, or ongoing antihypertensive treatment; fasting plasma glucose > 6.1 mmol/l (100 mg/dl) or ongoing antidiabetic treatment (24) .
Body mass index
Th e body mass index (BMI) was calculated as weight in kilograms divided by height in meters 2 and patients were classifi ed as underweight (<18.5 kg/m 2 ), normal (18.5-24.9 kg/m 2 ), overweight (25-29.9 kg/m 2 ), and obese (≥30.0 kg/m 2 ).
cardiovascular risk factors such as blood pressure and lipid levels. Methotrexate increases homocysteine levels (19) , whereas cyclosporine and acitretin induce hyperlipidemia (20) . Th us, high prevalence of some comorbidities in patients with psoriasis may be, at least partly, due to systemic antipsoriatic drugs. Wakkee at al. argue that eff ects of systemic drugs on the cardiovascular risk represent a sum of antiinfl ammatory eff ects and atherogenic side eff ects (18) . Th e objective of this study was to determine the prevalence of comorbidities in patients with psoriasis never treated with any systemic antipsoriatic drugs.
Material
Patients One hundred and twenty two patients with plaquetype psoriasis and 122 age and sex-matched controls participated in the study. Th e group of psoriatic patients included 44 inpatients (36.1%) and 78 outpatients (63.9%), who were consecutively recruited from the University Clinic of Dermatology, at Skopje Medical Faculty from September 2011 to April 2012. Th e inclusion criteria were age > 18 years and clinical diagnosis of plaque-type psoriasis lasting at least six months. Th e study included only systemically untreated patients. Th us, patients who received systemic antipsoriatic drugs, (eg. acitretin, cyclosporine, methotrexate, ultraviolet therapy, corticosteroids) or biologics, were excluded. In addition, patients with other types of psoriasis (guttate, erythrodermic and pustular psoriasis), history of SLE, RA and other autoimmune disorders were also excluded. Th e control group was selected from patients from the same geographic region, who were consecutively admitted/visited the Public Health Center "13 Noemvri", during the same period. Each control was matched to a case according to age (+/-1 year) and sex. Controls visited general practitioners for: routine control (59 patients), viral infection (15 patients), bacterial infection (11 patients) and hypertension (10 patients), dermatologic condition other than psoriasis (8 patients), cardiomyopathy (8 patients), diabetes (4 patients), urology problems (3 patients), gastroenteritis (2 patients), and trauma (2 patients).
Th e study was conducted through a structured face-to-face interview and examination, and it was
Results
Baseline characteristics of the study group are shown in Table 1 . One hundred and twenty-two patients with psoriasis (52 male and 70 female, the mean age 51.52 years, SD 15.56, range 19 -80 years), and 122 age-and gender-matched controls (52 males and 70 females, the mean age 51.98; years, SD 15.72, range 19 -79 years, participated in the study. Figure 2 shows their age and sex distribution. A close match between the groups can be seen. No statistically signifi cant diff erence was noted in the mean age and sex ratio between the groups (p=0.82 and p=1.00, respectively).
Disease characteristics
Type 1 psoriasis was found in 78 patients (63.9%). Th e mean age of psoriasis onset was 33.34 years (SD 17.14, range 1 -76). Th e mean duration of psoriasis was 17.9 years (SD14.21, range 1 -65 years). Psoriatic arthritis was present in 16 patients (13.1%). Th e mean age of PsA onset was 39.2 years (range 27 -59). Th e mean interval between the onset of psoriasis and onset of PsA was 6.67 years (SD 6.6). In 2 patients, arthritis developed before psoriasis was diagnosed. A positive family history of psoriasis was reported by 21 patients (17.21%), with a 92% incidence in firstdegree relatives.
PASI scores ranged from 2.4 to 62,0 (mean 14.75, SD 12.78) and 56 patients (45.9%) had moderate to severe psoriasis (PASI>10). BSA ranged
Blood pressure
Blood pressure (BP) was measured in sitting position using a standard mercury sphygmomanometer.
Smoking
Smoking habit was classifi ed into two categories of never smokers and ex-smokers/current smokers.
Alcohol consumption
Alcohol consumption was classifi ed into two categories of none/low/moderate: up to three alcoholic drinks per week, and regular/heavy: ≥ 4 alcoholic drinks per week.
Statistical analysis
Categorical variables were expressed as frequencies and percentages, and numerical variables as means, range and standard deviations (SD). Odds ratios (OR) were estimated using logistic regression models with conditional 95% confi dence intervals (CI). Th e proportion of comorbidities in psoriatic patients was compared with their matched non-psoriatic controls. Comparisons were made by using the Student's t-test for parametric continuous variables, Mann-Whitney U test for nonparametric continuous variables and Chi-square test for qualitative variables. Th e limit for statistical signifi cance was set at p ≤ 0.05. Th e SPSS version 10 statistical software (SPSS Inc., Chicago, Illinois, USA) was used for statistical analysis. Figure 3 shows distribution of patients according to the PASI score.
Th e prevalence of cardiovascular and metabolic comorbid conditions
Th ere were no signifi cant diff erences in the prevalence of hypertension (29.5% vs. 23.7%, p=0.311), coronary heart disease (13.9% vs. 17.2%, p=0.480), diabetes (9.0% vs. 7.3%, p=0.641), myocardial infarction (3.2% vs. 2.4%, p=0.71), stroke (2.4% vs. 2.4%, p=1.00) and metabolic syndrome (24.6% vs. 22.9%, p=0.764), between cases and controls (Table 2), (Figure 4) . Th e prevalence of hypertriglyceridemia in patients with psoriasis and controls was 41.8% and 28.7%, respectively (OR 1.78, 95% CI 1.04-3.04, p=0.032) (Table 2), (Figure 4 ). Furthermore, a signifi cant diff erence was found in mean triglyceride levels of patients and controls (170.19±67.84 mg/dL vs. 149.27±81.15 mg/dL, p=0.013). 
Lifestyle factors
Discussion
Psoriasis and cardiovascular risk
Th e relationship between psoriasis and increased risk of CVD remains controversial (25) . In general, most of the previous studies suggest that people with psoriasis are at increased risk of CVD (8-10, 16, 20, 26-28) . Th is was not confi rmed in a large prospective cohort study conducted by Stern and Lange (29) . Furthermore, two recent studies of general population (30, 31) demonstrated that the relationship between psoriasis and cardiovascular risk (CVR) is insignifi cant, and that traditional cardiovascular risk factors are signifi cantly associated with cardiovascular risk in psoriasis (30, 31) . Moreover, two population-based database studies that included pharmaceutical data did not confi rm the association between psoriasis and treatment of CVD (32, 33) . Mallbris et al. found a 50% greater risk of death from CVD among psoriatic inpatients, compared with the general population. In contrast, the overall risk of cardiovascular death was slightly decreased among outpatients with psoriasis (27) .
A recent meta-analysis of cardiovascular risk confi rms that psoriasis is related with an increased risk of cardiovascular mortality (28) . However, it remains unclear whether cardiovascular risk in Our study showed no signifi cant diff erence in the prevalence of coronary heart disease (CHD) (p=0.48), hypertension (p=0.31), myocardial infarction (p=0.71), stroke (p=1) and metabolic syndrome (p=0.76), between patients with psoriasis and controls.
Psoriasis and diabetes
In recent years it has been recognized that patients with psoriasis carry an increased risk of type 2 diabetes. Two meta-analyses have examined diabetes in psoriatic patients. Armstrong et al. conducted a meta-analysis of 27 observational studies and found that psoriasis is associated with a relative risk of 1.27 (95% CI 1.16 psoriasis is increased beyond that conferred by traditional cardiovascular risk factors. Samarasekera et al. evaluated 15 cohorts and meta-analyses of the magnitude of CVD risk for the primary outcomes of CVD mortality, stroke and myocardial infarction and identifi ed increased CVD risk only in people with severe psoriasis (defi ned as requiring systemic therapy or hospital admission). Th ey detected that majority of studies failed to adequately adjust for key traditional risk factors (25) .
In this matched case-control study, we found no diff erences between subjects with and without psoriasis, in regard to cardiovascular disease and major cardiovascular risk (CVR) factors. Th ey found that the risk of incident DM increased with psoriasis duration and severity (37) . It is well known that chronic systemic infl ammation of psoriasis induces endothelial dysfunction, altered glucose metabolism, and insulin resistance which all together play a signifi cant role in the development of obesity, diabetes mellitus, dyslipidemia, and cardiovascular disease (38) . It is also possible that patients with psoriasis use topical corticosteroids for long periods of time, which are systemically absorbed and contribute to the development of diabetes (37, 39 severity (45, 46) . Traditional systemic therapies for psoriasis may aggravate cardiovascular risk factors (19, 20) . Th us, high prevalence of CVD may be in part due to systemic antipsoriatic therapy. It is rather diffi cult to assess the independent contribution of systemic antipsoriatic drugs on the development of CVR in patients with psoriasis, since a certain number of concurrent factors, such as lifestyle factors, as well as other systemic drugs such as NSAIL, antidepressants and diuretics, needs to be taken into consideration, as these drugs are widely prescribed for patients with psoriasis (47) .
Psoriasis and traditional cardiovascular risk factors
Our study confi rms that psoriasis patients have three lifestyle/classic risk factors for CVD more frequently compared to controls: smoking, obesity and hypertriglyceridemia. Th e prevalence of smoking was higher in patients with psoriasis (41.8%) than in the control group (34.4%), and higher than in general population in Macedonia (35%) (48) . Psoriasis showed a statistically signifi cant association with BMI and obesity classifi cation. Th is fi nding is in agreement with most of the previously published studies. Th e major weakness of our study is its sample size, while its strength is its matched case-control design which controlled fundamental confounders of age and gender. Besides, both case and control subjects were selected from the same source population. All data (40) . In this case-control study, we found no diff erences between subjects with and without psoriasis in regard to diabetes (9.0% vs. 7.3%, p=0.641).
Th ere are several possible explanations for the diversity of fi ndings. Some studies are associated with high risk of selection and detection bias, due to the use of hospital records/administrative databases, and hospital/registry controls. Diff erences in various exposure factors, such as geographic-regional and ethnic, in genetic susceptibility and nutritional habits among diff erent populations may aff ect the prevalence of cardiovascular diseases and diabetes. Th us, the prevalence of diabetes in the Macedonian population is considered to be about 7.7%, which is similar to our fi ndings (41).
Finally, selection of untreated patients with psoriasis eliminates the infl uence of systemic antipsoriatic drugs on cardiovascular risks. To our knowledge, this is the fi rst case-control study on comorbidities in untreated patients with psoriasis. Only few studies considered drugs as a factor contributing to the development of CVD (42) . Gissondi et al. (42) and Nisa and al. (43) did not include patients receiving any systemic antipsoriatic treatment for at least one month before enrolment. Several other studies analyzed patients with new diagnosis of psoriasis (27, 44) . On the contrary, some studies used systemic treatment as a measure of disease were collected through interviews and measurements of disease activity were performed by an experienced dermatologist.
Conclusion
In conclusion, our data suggest that systemic antipsoriatic drugs may exert an important infl uence on the prevalence of cardiometabolic comobidity in patients with psoriasis. Furthermore, our study confi rms that untreated psoriatic patients have three major increased lifestyle cardiovascular risk factors: smoking, obesity and hypertrigliceridemia. Further research will explore the eff ects of systemic antipsoriatic drugs on these comorbid conditions in psoriasis. 
